Most Read Articles
Jairia Dela Cruz, 10 Apr 2019
Treatment with tofacitinib yields significant improvements in signs and symptoms of rheumatoid arthritis (RA) in patients from the Asia Pacific, according to data from a posthoc analysis. The drug has a safety profile consistent with global tofacitinib studies, although infections occur more frequently in Asians.
Jairia Dela Cruz, 30 Apr 2019
In rheumatoid arthritis (RA) patients in remission, increasing the dose interval of tocilizumab injection from the standard 162 mg once weekly to twice weekly may do more harm than good. Specifically, such a strategy is associated with a lower chance of remission maintenance as well as a lack of improvement in tolerability, as shown in a recent trial.
Jairia Dela Cruz, 29 Apr 2019
Physicians are likely to underestimate the severity of psoriatic arthritis (PsA) in patients who are older, show higher fatigue levels, complain of greater pain or have poorer mental health, according to a Singapore study. In contrast, overestimation of disease severity by physicians tends to occur in the presence of higher swollen joint counts.
Jairia Dela Cruz, 05 Jan 2017
Patients with early arthritis should be allowed to share in the decision making regarding the approach to treatment, with rheumatologists acting as the primary specialists, according to the 2016 update of the European League Against Rheumatism (EULAR) recommendations for early arthritis management.

Atorvastatin a promising cardioprotective agent in rheumatoid arthritis

13 May 2019

Use of atorvastatin in patients with rheumatoid arthritis (RA) is safe and leads to substantial reductions in low-density lipoprotein (LDL) cholesterol, which translates to a 40-percent decrease in the risk of cardiovascular events, according to data from the TRACE RA trial.

TRACE-RA randomized 3,002 RA patients (mean age, 61 years; 74 percent female) to receive atorvastatin 40 mg daily or matching placebo. None of the patients had clinical atherosclerosis, diabetes or myopathy.

Over a median follow-up of 2.51 years, the primary endpoint of a composite of cardiovascular death, myocardial infarction, stroke, transient ischaemic attack or any arterial revascularization occurred in 24 patients in the atorvastatin group and in 36 patients in the placebo group (1.6 percent vs 2.4 percent, respectively; adjusted hazard ratio, 0.60; 95 percent CI, 0.32–1.15; p=0.127).

The trial was terminated prematurely due to lower than expected event rate (0.77 percent per annum).

Results for the secondary endpoint of plasma lipids favoured atorvastatin. Compared with placebo, the statin yielded greater reductions in mean LDL cholesterol (2.21 vs 2.98 mmol/L; p<0.0001) and mean C-reactive protein (2.59 vs 3.60 mg/L; p<0.0001).

Every 1-mmol/L decrease in LDL cholesterol was associated with a 42-percent reduction in the risk of cardiovascular events.

Adverse events occurred similarly in the atorvastatin and placebo groups (19.8 percent vs 19.5 percent).

The findings suggest that once-daily atorvastatin 40 mg is safe for the primary prevention of cardiovascular events in patients with RA, conferring a similar magnitude of risk reduction in these patients as in other populations, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 10 Apr 2019
Treatment with tofacitinib yields significant improvements in signs and symptoms of rheumatoid arthritis (RA) in patients from the Asia Pacific, according to data from a posthoc analysis. The drug has a safety profile consistent with global tofacitinib studies, although infections occur more frequently in Asians.
Jairia Dela Cruz, 30 Apr 2019
In rheumatoid arthritis (RA) patients in remission, increasing the dose interval of tocilizumab injection from the standard 162 mg once weekly to twice weekly may do more harm than good. Specifically, such a strategy is associated with a lower chance of remission maintenance as well as a lack of improvement in tolerability, as shown in a recent trial.
Jairia Dela Cruz, 29 Apr 2019
Physicians are likely to underestimate the severity of psoriatic arthritis (PsA) in patients who are older, show higher fatigue levels, complain of greater pain or have poorer mental health, according to a Singapore study. In contrast, overestimation of disease severity by physicians tends to occur in the presence of higher swollen joint counts.
Jairia Dela Cruz, 05 Jan 2017
Patients with early arthritis should be allowed to share in the decision making regarding the approach to treatment, with rheumatologists acting as the primary specialists, according to the 2016 update of the European League Against Rheumatism (EULAR) recommendations for early arthritis management.